Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
CC transcript
Inv. presentation
Director comp.
|
|
Assertio Therapeutics, Inc (ASRT)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 04/22/2021 |
GN
| Assertio Holdings, Inc. to Report First Quarter 2021 Financial Results After the Close of Markets on Thursday, May 6, 2021 |
| 02/12/2021 |
GN
| Assertio Holdings, Inc. Announces Closing of Registered Direct Offering of $34.3 Million |
| 02/10/2021 |
GN
| Assertio Holdings, Inc. Announces Pricing of $34.3 Million Registered Direct Offering |
| 02/05/2021 |
GN
| Assertio Holdings, Inc. Announces Pricing of $14 Million Registered Direct Offering |
| 02/03/2021 |
GN
| Assertio Announces $5.0 Million Insurance Settlement and General Corporate Updates |
| 12/29/2020 |
GN
| Assertio Announces Transfer of Listing from Nasdaq Global Select Market to Nasdaq Capital Market |
| 12/15/2020 |
GN
| Assertio Announces Restructuring Plan and Leadership Changes |
| 11/06/2020 |
GN
| Assertio Reports Third Quarter 2020 Financial Results |
| 08/07/2020 |
GN
| Assertio Reports Second Quarter 2020 Financial Results |
| 07/20/2020 |
GN
| Assertio to Release Second Quarter 2020 Financial Results and Host Webcast on August 7, 2020 |
| 04/20/2020 |
GN
| Assertio Therapeutics Announces its Virtual 2020 Annual Meeting on May 19, 2020, and Mailing of its Joint Proxy Statement/Prospectus |
| 03/17/2020 |
GN
| Are Shareholders Getting a Fair Deal? Halper Sadeh LLP Investigates the Sale of These Companies – WLTW, TTPH, ASRT, MEET |
| 03/16/2020 |
GN
| Assertio Therapeutics Agrees to Merge with Zyla Life Sciences to Create Synergistic Portfolio of Neurology and Non-Opioid Pain Products |
| 03/09/2020 |
GN
| Assertio Therapeutics Announces Fourth-Quarter and Full-Year 2019 Financial Results |
| 03/02/2020 |
GN
| Assertio Therapeutics to Report Fourth Quarter and Full Year 2019 Financial Results After the Close of Markets on Monday, March 9, 2020 |
| 02/19/2020 |
GN
| Assertio Therapeutics Announces Repurchase of Approximately $188.0 Million of its Outstanding Convertible Debt |
| 02/13/2020 |
GN
| Assertio Therapeutics Announces Closing of Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million |
| 01/13/2020 |
GN
| Assertio Therapeutics Announces Closing of Gralise® Sale to Alvogen and Expects Full-Year 2019 Neurology Franchise Net Sales Above Upper End of Prior Guidance |
| 12/12/2019 |
GN
| Assertio Therapeutics Announces Sale of Gralise® for Total Transaction Value of $127.5 Million |
| 11/26/2019 |
GN
| Assertio Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference |
| 11/13/2019 |
GN
| Assertio Therapeutics to Present at the 2019 Stifel Healthcare Conference |
| 10/23/2019 |
GN
| Assertio Therapeutics to Report Third-Quarter 2019 Financial Results After the Close of Markets on Wednesday, November 6, 2019 |
| 10/21/2019 |
GN
| Assertio Therapeutics Provides Regulatory Update on Long-Acting Cosyntropin |
| 09/30/2019 |
GN
| Assertio Therapeutics Announces Appointment of Dr. David Wheadon to its Board of Directors |
| 09/26/2019 |
GN
| Assertio Therapeutics to Present at the Annual Cantor Fitzgerald Global Healthcare Conference |
| 08/09/2019 |
GN
| Assertio Therapeutics Announces Exchange Offer of $200 Million of its Currently Outstanding 2.50% Convertible Notes Due 2021 |
| 07/17/2019 |
GN
| Assertio Therapeutics to Report Second Quarter 2019 Financial Results After The Close of Markets on Wednesday, August 7, 2019 |
| 04/24/2019 |
GN
| Assertio Therapeutics to Report First Quarter 2019 Financial Results After The Close of Markets on Wednesday, May 8, 2019 |
| 04/01/2019 |
GN
| Assertio Therapeutics Announces Appointment of Jay Galeota to Board of Directors |
| 03/28/2019 |
GN
| Assertio Therapeutics Announces Favorable NUCYNTA® Patent Ruling |
| 02/19/2019 |
GN
| Assertio Therapeutics Announces FDA Notification of Acceptance for Filing of 505(b)(2) NDA for Long-acting Cosyntropin |
| 01/09/2019 |
GN
| Assertio Therapeutics Announces Amendment of its Senior Secured Credit Facility |
| 12/20/2018 |
GN
| Assertio Therapeutics Announces Submission of NDA for FDA Approval of Cosyntropin Depot |
| 08/15/2018 |
GN
| Depomed Inc. Announces Corporate Name Change to Assertio Therapeutics, Inc. |
|
|
|